Deals
High-Flier Pharmacyclics Picks Right Time for Sale
Micrograph of a large B-cell lymphoma.
Source: NephronThis article is for subscribers only.
There’s never been a better time for Pharmacyclics Inc. to consider a sale.
The developer of cancer treatments was trading at a record even before surging as much as 23 percent Wednesday after people familiar with the matter said it’s exploring a sale and has attracted Johnson & Johnson and Novartis AG.